Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2007:57–80. doi: 10.1007/978-1-59745-199-4_3

The Role of Phosphoinositide 3-Kinase-Akt Signaling in Virus Infection

Samantha Cooray 2
Editor: Rakesh Srivastava1
PMCID: PMC7120950

Summary

Successful virus infection of host cells requires efficient viral replication, production of virus progeny and spread of newly synthesized virus particles. This success, however also depends on the evasion of a multitude of antiviral signaling mechanisms. Many viruses are capable of averting antiviral signals through modulation of host cell signaling pathways. Apoptotic inhibition, for example, is a universal intracellular antiviral response, which prolongs cellular survival and allows viruses to complete their life cycle. Ongoing apoptotic inhibition contributes to the establishment of latent and chronic infections, and has been implicated in viral oncogenesis. The phosphoinositide 3-kinase (PI3K)-Akt pathway has become recognized as being pivotal to the inhibition of apoptosis and cellular survival. Thus, modulation of this pathway provides viruses with a mechanism whereby they can increase their survival, in addition to other established mechanisms such as expression of viral onco-genes and direct inhibition of proapoptotic proteins. Recent research has revealed that this pathway is up-regulated by a number of viruses during both short-term acute infections and long-term latent or chronic infections. During acute infections PI3K-Akt signaling helps to create an environment favorable for virus replication and virion assembly. In the case of long-term infections, modulation of PI3K-Akt signaling by specific viral products is believed to help create a favorable environment for virus persistence, and contribute to virus-mediated cellular transformation.

Key Words: Phosphoinositide 3-kinase, Akt, virus, transformation, signaling, survival

References

  • 1.Roulston A., Marcellus R.C., Branton P.E. Viruses and apoptosis. Annu Rev Microbiol. 1999;53:577–628. doi: 10.1146/annurev.micro.53.1.577. [DOI] [PubMed] [Google Scholar]
  • 2.Cantrell D.A. Phosphoinositide 3-kinase signalling pathways. J Cell Sci. 2001;114:1439–1445. doi: 10.1242/jcs.114.8.1439. [DOI] [PubMed] [Google Scholar]
  • 3.Chan T.O., Rittenhouse S.E., Tsichlis P.N. AKT/PKB and other D3 phosphoinositideregulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem. 1999;68:965–1014. doi: 10.1146/annurev.biochem.68.1.965. [DOI] [PubMed] [Google Scholar]
  • 4.Chang F., Lee J.T., Navalonic P.M., et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17:590–603. doi: 10.1038/sj.leu.2402824. [DOI] [PubMed] [Google Scholar]
  • 5.Vanhaesebroeck B., Leevers S.J., Ahmadi K., et al. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem. 2001;70:535–602. doi: 10.1146/annurev.biochem.70.1.535. [DOI] [PubMed] [Google Scholar]
  • 6.Vanhaesebroeck B., Waterfield M.D. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res. 1999;253:239–254. doi: 10.1006/excr.1999.4701. [DOI] [PubMed] [Google Scholar]
  • 7.Vanhaesebroeck B., Leevers S.J., Panayotou G., Waterfield M.D. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci. 1997;22:267–272. doi: 10.1016/S0968-0004(97)01061-X. [DOI] [PubMed] [Google Scholar]
  • 8.Yu J., Zhang Y., McIlroy J., Rordorf-Nikolic T., Orr G.A., Backer J.M. Regulation of the p85/p110 phosphatidylinositol 3?-kinase: stabilization and inhibition of the p110alpha catalytic subunit by the p85 regulatory subunit. Mol Cell Biol. 1998;18:1379–1387. doi: 10.1128/mcb.18.3.1379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Skolnik E.Y., Margolis B., Mohammadi M., et al. Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell. 1991;65:83–90. doi: 10.1016/0092-8674(91)90410-Z. [DOI] [PubMed] [Google Scholar]
  • 10.Carpenter C.L., Auger K.R., Chanudhuri M., et al. Phosphoinositide 3-kinase is activated by phosphopeptides that bind to the SH2 domains of the 85-kDa subunit. J Biol Chem. 1993;268:9478–9483. [PubMed] [Google Scholar]
  • 11.Nolte R.T., Eck M.J., Schlessinger J., Shoelson S.E., Harrison S.C. Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes. Nat Struct Biol. 1996;3:364–374. doi: 10.1038/nsb0496-364. [DOI] [PubMed] [Google Scholar]
  • 12.Shoelson S.E., Sivaraja M., Williams K.P., Hu P., Schlessinger J., Weiss M.A. Specific phosphopeptide binding regulates a conformational change in the PI 3-kinase SH2 domain associated with enzyme activation. EMBO J. 1993;12:795–802. doi: 10.1002/j.1460-2075.1993.tb05714.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Cipres A., Carrasco S., Merida I. Deletion of the acidic-rich domain of the IL-2Rbeta chain increases receptor-associated PI3K activity. FEBS Lett. 2001;500:99–104. doi: 10.1016/S0014-5793(01)02594-7. [DOI] [PubMed] [Google Scholar]
  • 14.Gonzalez-Garcia A., Merida I., Martinez A.C., Carrera A.C. Intermediate affinity interleukin-2 receptor mediates survival via a phosphatidylinositol 3-kinase-dependent pathway. J Biol Chem. 1997;272:10220–10226. doi: 10.1074/jbc.272.15.10220. [DOI] [PubMed] [Google Scholar]
  • 15.Vanhaesebroeck B., Alessi D.R. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J. 2000;346:561–576. doi: 10.1042/0264-6021:3460561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Stephens L., Smrcha A., Cooke F., Jackson T., Sternweis P., Hawkins P. A novel phosphoinositide 3 kinase activity in myeloid-derived cells is activated by G protein bg subunits. Cell. 1994;77:83–93. doi: 10.1016/0092-8674(94)90237-2. [DOI] [PubMed] [Google Scholar]
  • 17.Yan J., Roy S., Apolloni A., Lane A., Hancock J.F. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem. 1998;273:24052–24056. doi: 10.1074/jbc.273.37.24052. [DOI] [PubMed] [Google Scholar]
  • 18.Rodriguez-Viciana P., Warne P.H., Dhand R., et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature. 1994;370:527–532. doi: 10.1038/370527a0. [DOI] [PubMed] [Google Scholar]
  • 19.Rodriguez-Viciana P., Warne P.H., Vanhaesebroeck B., Waterfield M.D., Downward J. Activation of phosphoinositide 3-kinase by interaction with Ras and by point mutation. EMBO J. 1996;15:2442–2451. [PMC free article] [PubMed] [Google Scholar]
  • 20.Hawkins P.T., Jackson T.R., Stephens L.R. Platelet-derived growth factor stimulates synthesis of PtdIns(3,4,5)P3 by activating a PtdIns(4,5)P2 3-OH. Nature. 1992;358:157–159. doi: 10.1038/358157a0. [DOI] [PubMed] [Google Scholar]
  • 21.Maehama T., Dixon J.E. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 1999;9:125–128. doi: 10.1016/S0962-8924(99)01519-6. [DOI] [PubMed] [Google Scholar]
  • 22.Leslie N.R., Downes C.P., Maehama T., Dixon J.E. PTEN: The down side of PI3-kinase signaling. Cell Signal. 2002;14:285–295. doi: 10.1016/S0898-6568(01)00234-0. [DOI] [PubMed] [Google Scholar]
  • 23.Bottomley M.J., Salim K., Panayotou G. Phospholipid-binding protein domains. Biochim Biophys Acta. 1998;1436:165–183. doi: 10.1016/s0005-2760(98)00141-6. [DOI] [PubMed] [Google Scholar]
  • 24.Staal S.P., Hartley J.W., Rowe W.P. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma. Proc Natl Acad Sci USA. 1977;74:3065–3067. doi: 10.1073/pnas.74.7.3065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Bellacosa A., Testa J.R., Staal S.P., Tsichlis P.N. A retroviral oncogene, akt, encoding a serinethreonine kinase containing an SH2-like region. Science. 1991;254:274–277. doi: 10.1126/science.1833819. [DOI] [PubMed] [Google Scholar]
  • 26.Jones P.F., Jakubowicz T., Pitossi F.J., Maurer F., Hemmings B.A. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. Proc Natl Acad Sci USA. 1991;88:4171–4175. doi: 10.1073/pnas.88.10.4171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Coffer P.J., Woodgett J.R. Molecular cloning and characterisation of a novel putative proteinserine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem. 1991;201:475–481. doi: 10.1111/j.1432-1033.1991.tb16305.x. [DOI] [PubMed] [Google Scholar]
  • 28.Scheid M.P., Woodgett J.R. Unraveling the activation mechanism of protein kinase B/Akt. FEBS letters. 2003;546:108–112. doi: 10.1016/S0014-5793(03)00562-3. [DOI] [PubMed] [Google Scholar]
  • 29.Lawlor M.A., Alessi D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci. 2001;114:2903–2910. doi: 10.1242/jcs.114.16.2903. [DOI] [PubMed] [Google Scholar]
  • 30.Datta S.R., Dudek H., Tao X., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231–241. doi: 10.1016/S0092-8674(00)80405-5. [DOI] [PubMed] [Google Scholar]
  • 31.Cardone M.H., Roy N., Stennicke H.R., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science. 1998;282:1318–1321. doi: 10.1126/science.282.5392.1318. [DOI] [PubMed] [Google Scholar]
  • 32.Pap M., Cooper G.M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem. 1998;273:19929–19932. doi: 10.1074/jbc.273.32.19929. [DOI] [PubMed] [Google Scholar]
  • 33.Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378:785–789. doi: 10.1038/378785a0. [DOI] [PubMed] [Google Scholar]
  • 34.Burgering B.M., Medema R.H. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leukoc Biol. 2003;73:689–701. doi: 10.1189/jlb.1202629. [DOI] [PubMed] [Google Scholar]
  • 35.Rena G., Guo S., Cichy S.C., Unterman T.G., Cohen P. Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B. J Biol Chem. 1999;274:17179–17183. doi: 10.1074/jbc.274.24.17179. [DOI] [PubMed] [Google Scholar]
  • 36.Khwaja A. Akt is more than just a Bad kinase. Nature. 1999;401:33–34. doi: 10.1038/43354. [DOI] [PubMed] [Google Scholar]
  • 37.Ozes O.N., Mayo L.D., Gustin J.A., Pfeffer S.R., Pfeffer L.M., Donner D.B. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature. 1999;401:82–85. doi: 10.1038/43466. [DOI] [PubMed] [Google Scholar]
  • 38.Yang C.H., Murti A., Pfeffer S.R., Kim J.G., Donner D.B., Pfeffer L.M. Interferon alpha/beta promotes cell survival by activating nuclear factor kappa B through phosphatidylinositol 3-kinase and Akt. J Biol Chem. 2001;276:13756–13761. doi: 10.1074/jbc.M011006200. [DOI] [PubMed] [Google Scholar]
  • 39.Romashkova J.A., Makarov S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature. 1999;401:86–90. doi: 10.1038/43474. [DOI] [PubMed] [Google Scholar]
  • 40.Hatano E., Brenner D.A. Akt protects mouse hepatocytes from TNF-alpha-and Fas-mediated apoptosis through NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol. 2001;281:G1357–G1368. doi: 10.1152/ajpgi.2001.281.6.G1357. [DOI] [PubMed] [Google Scholar]
  • 41.Collins P.L., Chanock R.M., Murphy B.R., et al. Respiratory Syncytial Virus. In: Knipe D.M., Howley P.M., Griffin D.E., et al., editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 1443–1486. [Google Scholar]
  • 42.Bitko V., Velazquez A., Yang L., Yang Y.C., Barik S. Transcriptional induction of multiple cytokines by human respiratory syncytial virus requires activation of NF-kappa B and is inhibited by sodium salicylate and aspirin. Virology. 1997;232:369–378. doi: 10.1006/viro.1997.8582. [DOI] [PubMed] [Google Scholar]
  • 43.Haeberle H.A., Takizawa R., Casola A., et al. Respiratory syncytial virus-induced activation of nuclear factor-kappa B in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways. J Infect Dis. 2002;186:1199–1206. doi: 10.1086/344644. [DOI] [PubMed] [Google Scholar]
  • 44.Kong X., San Juan H., Kumar M., et al. Respiratory syncytial virus infection activates STAT signaling in human epithelial cells. Biochem Biophys Res Commun. 2003;306:616–622. doi: 10.1016/S0006-291X(03)01008-8. [DOI] [PubMed] [Google Scholar]
  • 45.Thomas K.W., Monick M.M., Staber J.M., Yarovinsky T., Carter A.B., Hunninghake G.W. Respiratory syncytial virus inhibits apoptosis and induces NF-kappa B activity through a phosphatidylinositol 3-kinase-dependent pathway. J Biol Chem. 2002;277:492–501. doi: 10.1074/jbc.M108107200. [DOI] [PubMed] [Google Scholar]
  • 46.Monick M.M., Cameron K., Powers L.S., et al. Spingosine kinase mediates activation of extracellular signal related kinase and Akt by respiratory syncytial virus. Am J Respir Cell Mol Biol. 2004;30:844–852. doi: 10.1165/rcmb.2003-0424OC. [DOI] [PubMed] [Google Scholar]
  • 47.Cooray S., Jin L., Best J.M. The involvement of survival signaling pathways in rubella-virus induced apoptosis. Virol J. 2005;2:1. doi: 10.1186/1743-422X-2-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Cooray S., Best J.M., Jin L. Time-course induction of apoptosis by wild-type and attenuated strains of rubella virus. J Gen Virol. 2003;84:1275–1279. doi: 10.1099/vir.0.18785-0. [DOI] [PubMed] [Google Scholar]
  • 49.Domegan L.M., Atkins G.J. Apoptosis induction by the Therien and vaccine RA27/3 strains of rubella virus causes depletion of oligodendrocytes from rat neural cell cultures. J Gen Virol. 2002;83:2135–2143. doi: 10.1099/0022-1317-83-9-2135. [DOI] [PubMed] [Google Scholar]
  • 50.Duncan R., Muller J., Lee N., Esmaili A., Nakhasi H.L. Rubella virus-induced apoptosis varies among cell lines and is modulated by Bcl-XL and caspase inhibitors. Virology. 1999;255:117–128. doi: 10.1006/viro.1998.9562. [DOI] [PubMed] [Google Scholar]
  • 51.Hofmann J., Pletz M.W., Liebert U.G. Rubella virus-induced cytopathic effect in vitro is caused by apoptosis. J Gen Virol. 1999;80:1657–1664. doi: 10.1099/0022-1317-80-7-1657. [DOI] [PubMed] [Google Scholar]
  • 52.Pugachev K.V., Frey T.K. Rubella virus induces apoptosis in culture cells. Virology. 1998;250:359–370. doi: 10.1006/viro.1998.9395. [DOI] [PubMed] [Google Scholar]
  • 53.Kronfield I., Kazimirsky G., Gelfand E.W., Brodie C. NGF rescues human B lymphocytes from anti-IgM induced apoptosis by activation of PKC. Eur J Immunol. 2002;32:136–143. doi: 10.1002/1521-4141(200201)32:1<136::AID-IMMU136>3.0.CO;2-T. [DOI] [PubMed] [Google Scholar]
  • 54.Mizutani T., Fukushi S., Masayuki S., Kurane I., Morikawa S. Importance of Akt signaling pathway for apoptosis in SARS-CoV-infected Vero E6 cells. Virology. 2004;327:169–174. doi: 10.1016/j.virol.2004.07.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Carthy C.M., Granville D.J., Watson K.A., et al. Caspase activation and specific cleavage of substrates after coxsackievirus B3-induced cytopathic effect in HeLa cells. J Virol. 1998;72:7669–7675. doi: 10.1128/jvi.72.9.7669-7675.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Joo C.H., Hong H.N., Kim E.O., et al. Coxsackievirus B3 induces apoptosis in the early phase of murine myocarditis: a comparative analysis of cardiovirulent and noncardiovirulent strains. Intervirology. 2003;46:135–140. doi: 10.1159/000071453. [DOI] [PubMed] [Google Scholar]
  • 57.Esfandiarei M., Luo H., Yanagawa B., et al. Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent. J Virol. 2004;78:4289–4298. doi: 10.1128/JVI.78.8.4289-4298.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Tyler K.L., Nathanson N., et al. Pathogenesis of Viral Infections. In: Knipe D.M., Howley P.M., Griffin D.E., et al., editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 199–244. [Google Scholar]
  • 59.Kieff E., Rickinson A.B., et al. Epstein-Barr Virus and Its Replication. In: Knipe D.M., Howley P.M., Griffin D.E., et al., editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 2511–2574. [Google Scholar]
  • 60.Bale J.F., Blackman J.A., Sato Y. Outcome in children with symptomatic congenital cytomeglovirus infection. J Child Neurol. 1990;5:131–136. doi: 10.1177/088307389000500212. [DOI] [PubMed] [Google Scholar]
  • 61.Pass R.F., et al. Cytomeglovirus. In: Knipe D.M., Howley P.M., Griffin D.E., et al., editors. Feilds Virology. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 2675–2706. [Google Scholar]
  • 62.Yurochko A.D., Hwang E.S., Rasmussen L., Keay S., Pereira L., Huang E.S. The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection. J Virol. 1997;71:5051–5059. doi: 10.1128/jvi.71.7.5051-5059.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Yurochko A.D., Mayo M.W., Poma E.E., Baldwin A.S., Jr., Huang E.S. Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-kB promoters. J Virol. 1997;71:4638–4648. doi: 10.1128/jvi.71.6.4638-4648.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Johnson R.A., Huong S.M., Huang E.S. Activation of the mitogen-activated protein kinase p38 by human cytomegalovirus infection through two distinct pathways: a novel mechanism for activation of p38. J Virol. 2000;74:1158–1167. doi: 10.1128/JVI.74.3.1158-1167.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Bresnahan W.A., Thompson E.A., Albrecht T. Human cytomegalovirus infection results in altered Cdk2 subcellular localization. J Gen Virol. 1997;78:1993–1997. doi: 10.1099/0022-1317-78-8-1993. [DOI] [PubMed] [Google Scholar]
  • 66.Johnson R.A., Ma X.L., Yurochko A.D., Huang E.S. The role of MKK1/2 kinase activity in human cytomegalovirus infection. J Gen Virol. 2001;82:493–497. doi: 10.1099/0022-1317-82-3-493. [DOI] [PubMed] [Google Scholar]
  • 67.Johnson R.A., Wang X., Ma X.L., Huong S.M., Huang E.S. Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J Virol. 2001;75:6022–6032. doi: 10.1128/JVI.75.13.6022-6032.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Johnson M.D., Okedli E., Woodard A., Toms S.A., Allen G.S. Evidence for phosphatidylinositol 3-kinase-Akt-p70S6K pathway activation and transduction of mitogenic signals by plateletderived growth factor in meningioma cells. J Neurosurg. 2002;97:668–675. doi: 10.3171/jns.2002.97.3.0668. [DOI] [PubMed] [Google Scholar]
  • 69.Weng Q.P., Andrabi K., Kozlowski M.T., Grove J.R., Avruch J. Multiple independent inputs are required for activation of the p70 S6 kinase. Mol Cell Biol. 1995;15:2333–2340. doi: 10.1128/mcb.15.5.2333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Katz B.Z., Raab-Traub N., Miller G. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases. J Infect Dis. 1989;160:589–598. doi: 10.1093/infdis/160.4.589. [DOI] [PubMed] [Google Scholar]
  • 71.Raab-Traub N., Flynn K., Pearson G., et al. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int J Cancer. 1987;39:25–29. doi: 10.1002/ijc.2910390106. [DOI] [PubMed] [Google Scholar]
  • 72.Rickinson A.B., Kieff E., et al. Epstein-Barr Virus. In: Knipe D.M., Howley P.M., Griffin D.E., et al., editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2001. pp. 2575–2628. [Google Scholar]
  • 73.Gires O., Zimber-Strobl U., Gonnella R., et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 1997;16:6131–6140. doi: 10.1093/emboj/16.20.6131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Izumi K.M., Cahir McFarland E.D., Ting A.T., Riley E.A., Seed B., Kieff E.D. The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptor-interacting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation. Mol Cell Biol. 1999;19:5759–5767. doi: 10.1128/mcb.19.8.5759. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Mosialos G., Birkenbach M., Yalamanchili R., Van Arsdale T., Ware C., Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell. 1995;80:389–399. doi: 10.1016/0092-8674(95)90489-1. [DOI] [PubMed] [Google Scholar]
  • 76.Eliopoulos A.G., Young L.S. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) Oncogene. 1998;16:1731–1742. doi: 10.1038/sj.onc.1201694. [DOI] [PubMed] [Google Scholar]
  • 77.Gires O., Kohlhuber F., Kilger E., et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 1999;18:3064–3073. doi: 10.1093/emboj/18.11.3064. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 78.Roberts M.L., Cooper N.R. Activation of a ras-MAPK-dependent pathway by Epstein-Barr virus latent membrane protein 1 is essential for cellular transformation. Virology. 1998;240:93–99. doi: 10.1006/viro.1997.8901. [DOI] [PubMed] [Google Scholar]
  • 79.Dawson C.W., Tramountanis G., Eliopoulos A.G., Young L.S. Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodelling. J Biol Chem. 2003;278:3694–3704. doi: 10.1074/jbc.M209840200. [DOI] [PubMed] [Google Scholar]
  • 80.Swart R., Ruf I.K., Sample J., Longnecker R. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway. J Virol. 2000;74:10838–10845. doi: 10.1128/JVI.74.22.10838-10845.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 81.Portis T., Longnecker R. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene. 2004;2004:8619–8628. doi: 10.1038/sj.onc.1207905. [DOI] [PubMed] [Google Scholar]
  • 82.Scholle F., Bendt K.M., Raab-Traub N. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol. 2000;74:10681–10689. doi: 10.1128/JVI.74.22.10681-10689.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 83.Fukuda M., Longnecker R. Latent membrane protein 2A inhibits transforming growth factor-b1-indiced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. J Virol. 2004;78:1697–1705. doi: 10.1128/JVI.78.4.1697-1705.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.Flemington E., Speck S.H. Epstein-Barr virus BZLF1 trans activator induces the promoter of a cellular cognate gene, c-fos. J Virol. 1990;64:4549–4552. doi: 10.1128/jvi.64.9.4549-4552.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Zalani S., Holley-Guthrie E., Kenney S. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci USA. 1996;93:9194–9199. doi: 10.1073/pnas.93.17.9194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Darr D.C., Mauser A., Kenney S. Epstein-Barr virus immediate-early protein BRLF1 induces the lytic form of viral replication through a mechanism involving phosphatidylinositol-3 kinase activation. J Virol. 2001;75:6135–6142. doi: 10.1128/JVI.75.13.6135-6142.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Chang Y., Moore P.S. Kaposi’s Sarcoma (KS)-associated herpesvirus and its role in KS. Infect Agents Dis. 1996;5:215–222. [PubMed] [Google Scholar]
  • 88.Antman K., Chang Y. Kaposi’s sarcoma. N Engl J Med. 2000;342:1027–1038. doi: 10.1056/NEJM200004063421407. [DOI] [PubMed] [Google Scholar]
  • 89.Gallo R.C. The enigmas of Kaposi’s sarcoma. Science. 1998;282:1837–1839. doi: 10.1126/science.282.5395.1837. [DOI] [PubMed] [Google Scholar]
  • 90.Chang Y., Cesarman E., Pessin M.S., et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;265:1865–1869. doi: 10.1126/science.7997879. [DOI] [PubMed] [Google Scholar]
  • 91.Bais C., Santomasso B., Coso O., et al. G-protein-coupled receptor of Kaposi’s sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator. Nature. 1998;391:86–89. doi: 10.1038/34193. [DOI] [PubMed] [Google Scholar]
  • 92.Cheng E.H., Nicholas J., Bellows D.S., et al. A Bcl-2 homolog encoded by Kaposi’s sarcomaassociated virus, human herpesvirus 8, inhibits apoptosis but does not heterodimerize with Bax or Bak. Proc Natl Acad Sci USA. 1997;94:690–694. doi: 10.1073/pnas.94.2.690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Moore P.S., Boshoff C., Weiss R.A., Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science. 1996;274:1739–1744. doi: 10.1126/science.274.5293.1739. [DOI] [PubMed] [Google Scholar]
  • 94.Lee H., Guo J., Li M., et al. Indentification of an immunoreceptor tyrosine-based activation motif of K1 transforming protein of Kaposi’s sarcoma-associated herpesvirus. Nat Med. 1998;404:782–787. doi: 10.1128/mcb.18.9.5219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Lagunoff M., Majeti A., Weiss A., Ganem D. Deregulated signal transduction by the K1 gene product of Kaposi’s sarcoma-associated herpesvirus. Proc Natl Acad Sci USA. 1999;96:5704–5709. doi: 10.1073/pnas.96.10.5704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Tomlinson C.C., Damania B. The K1 protein of Kaposi’s sarcoma-associated herpesvirus activates the Akt signaling pathway. J Virol. 2004;78:1918–1927. doi: 10.1128/JVI.78.4.1918-1927.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 97.zur Hausen H., de Villiers E.M. Human papillomaviruses. Annu Rev Microbiol. 1994;48:427–447. doi: 10.1146/annurev.micro.48.1.427. [DOI] [PubMed] [Google Scholar]
  • 98.zur Hausen H. Papillomaviruses and cancer: from basic studies to clincal application. Nat Rev Cancer. 2002;2:342–350. doi: 10.1038/nrc798. [DOI] [PubMed] [Google Scholar]
  • 99.Zhang B., Spandau D.F., Roman A. E5 protein of human papillomavirus type 16 protects human foreskin keratinocyes from UV B-irradiation-induced apoptosis. J Virol. 2002;76:220–231. doi: 10.1128/JVI.76.1.220-231.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Crusius K., Auvinen E., Steuer B., Gaissert H., Alonso A. The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Exp Cell Res. 1998;241:76–83. doi: 10.1006/excr.1998.4024. [DOI] [PubMed] [Google Scholar]
  • 101.Hwang E.S., Nottoli T., Dimaio D. The HPV-16 E5 protein: expression, detection, and stable complex formation with transmembrane proteins in COS cells. Virology. 1995;211:227–233. doi: 10.1006/viro.1995.1395. [DOI] [PubMed] [Google Scholar]
  • 102.Hawley-Nelson P., Vousden K.H., Hubbert N.L., Lowy D.R., Schiller J.T. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J. 1989;8:3905–3910. doi: 10.1002/j.1460-2075.1989.tb08570.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Kaur P., McDougall J.K., Cone R. Immortalization of primary human epithelial cells by cloned cervical carcinoma DNA containing human papillomavirus type 16 E6/E7 open reading frames. J Gen Virol. 1989;70:1261–1266. doi: 10.1099/0022-1317-70-5-1261. [DOI] [PubMed] [Google Scholar]
  • 104.Munger K., Phelps W.C., Bubb V., Howley P.M., Schlegl R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol. 1989;63:4417–4421. doi: 10.1128/jvi.63.10.4417-4421.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Gottlieb K.A., Villarreal L.P. Natural biology of polyomavirus middle T antigen. Microbiol Mol Biol Rev. 2001;65:288–318. doi: 10.1128/MMBR.65.2.288-318.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 106.Campbell K.S., Ogris E., Burke B., et al. Polyoma middle tumor antigen interacts with SHC via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen. Proc Natl Acad Sci USA. 1994;91:6344–6348. doi: 10.1073/pnas.91.14.6344. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Su W., Liu W., Schaffhausen B.S., Roberts T.M. Association of Polyomavirus middle tumor antigen with phospholipase C-gamma 1. J Biol Chem. 1995;270:12331–12334. doi: 10.1074/jbc.270.26.15463. [DOI] [PubMed] [Google Scholar]
  • 108.Whitman M., Kaplan D.R., Schaffhausen B., Cantley L., Roberts T.M. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature. 1985;315:239–242. doi: 10.1038/315239a0. [DOI] [PubMed] [Google Scholar]
  • 109.Dahl J., Jurczak A., Cheng L.A., Baker D.C., Benjamin T.L. Evidence of a role for phosphatidylinositol 3-kinase activation in the blocking of apoptosis by polyomavirus middle T antigen. J Virol. 1998;72:3221–3226. doi: 10.1128/jvi.72.4.3221-3226.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Summers S.A., Lipfert L., Birnbaum M.J. Polyoma middle T antigen activates the Ser/Thr kinase Akt in a PI3-kinase-dependent manner. Biochem Biophys Res Commun. 1998;246:76–81. doi: 10.1006/bbrc.1998.8575. [DOI] [PubMed] [Google Scholar]
  • 111.Murakami S. Hepatitis B virus X protein: structure, function and biology. Intervirology. 1999;42:81–99. doi: 10.1159/000024969. [DOI] [PubMed] [Google Scholar]
  • 112.Benn J., Schneider R.J. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci USA. 1994;91:10350–10354. doi: 10.1073/pnas.91.22.10350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Benn J., Su F., Doria M., Schneider R.J. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-Jun N-terminal mitogenactivated protein kinases. J Virol. 1996;70:4978–4985. doi: 10.1128/jvi.70.8.4978-4985.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 114.Lee Y.I., Kang-Park S., Do S.I. The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J Biol Chem. 2001;276:16969–16977. doi: 10.1074/jbc.M011263200. [DOI] [PubMed] [Google Scholar]
  • 115.Shih W.L., Kuo M.L., Chuang S.E., Cheng A.L., Doong S.L. Hepatitis B virus X protein inhibits transforming growth factor-beta-induced apoptosis through the activation of phosphatidylinositol 3-kinase pathway. J Biol Chem. 2000;275:25858–25864. doi: 10.1074/jbc.M003578200. [DOI] [PubMed] [Google Scholar]
  • 116.Shih W.L., Kuo M.L., Chuang S.E., Cheng A.L., Doong S.L. Hepatitis B virus X protein activates a survival signaling by linking SRC to phosphatidylinositol 3-kinase. J Biol Chem. 2003;278:31807–31813. doi: 10.1074/jbc.M302580200. [DOI] [PubMed] [Google Scholar]
  • 117.Enamoto N., Sakuma I., Asahina Y., et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334:77–81. doi: 10.1056/NEJM199601113340203. [DOI] [PubMed] [Google Scholar]
  • 118.Lan K.H., Sheu M.L., Hwang S.J., et al. HCV NS5A interacts with p53 and inhibits p53-mediated apoptosis. Oncogene. 2002;21:4801–4811. doi: 10.1038/sj.onc.1205589. [DOI] [PubMed] [Google Scholar]
  • 119.Qadri I., Iwahashi M., Simon F. Hepatitis C virus NS5A protein binds TBP and p53, inhibiting their DNA binding and p53 interactions with TBP and ERCC3. Biochim Biophys Acta. 2002;1592:193–204. doi: 10.1016/s0167-4889(02)00315-4. [DOI] [PubMed] [Google Scholar]
  • 120.Tan S.L., Nakao H., He Y., et al. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/liganddependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci USA. 1999;96:5533–5538. doi: 10.1073/pnas.96.10.5533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 121.Georgopoulou U., Caravokiri K., Mavromara P. Suppression of the ERK1/2 signaling pathway from HCV NS5A protein expressed by herpes simplex recombinant viruses. Arch Virol. 2003;148:237–251. doi: 10.1007/s00705-002-0925-0. [DOI] [PubMed] [Google Scholar]
  • 122.He Y., Nakao H., Tan S.L., et al. Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. J Virol. 2002;76:9207–9217. doi: 10.1128/JVI.76.18.9207-9217.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Macdonald A., Crowder K., Street A., McCormick C., Harris M. The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity. J Gen Virol. 2004;85:721–729. doi: 10.1099/vir.0.19691-0. [DOI] [PubMed] [Google Scholar]
  • 124.Street A., Macdonald A., Crowder K., Harris M. The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J Biol Chem. 2004;279:12232–12241. doi: 10.1074/jbc.M312245200. [DOI] [PubMed] [Google Scholar]
  • 125.Choe H., Farzan M., Sun Y., et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 1996;85:1135–1148. doi: 10.1016/S0092-8674(00)81313-6. [DOI] [PubMed] [Google Scholar]
  • 126.Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872–877. doi: 10.1126/science.272.5263.872. [DOI] [PubMed] [Google Scholar]
  • 127.Dalgleish A.G., Beverley P.C., Clapham P.R., Crawford D.H., Greaves M.F., Weiss R.A. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature. 1984;312:763–767. doi: 10.1038/312763a0. [DOI] [PubMed] [Google Scholar]
  • 128.Briand G., Barbeau B., Tremblay M. Binding of HIV-1 to its receptor induces tyrosine phosphorylation of several CD4-associated proteins, including the phosphatidylinositol 3-kinase. Virology. 1997;228:171–179. doi: 10.1006/viro.1996.8399. [DOI] [PubMed] [Google Scholar]
  • 129.Francois F., Klotman M.E. Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages. J Virol. 2003;77:2539–2549. doi: 10.1128/JVI.77.4.2539-2549.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 130.Arora V.K., Fredericksen B.L., Garcia J.V. Nef: agent of cell subversion. Microbes Infect. 2002;4:189–199. doi: 10.1016/S1286-4579(01)01527-1. [DOI] [PubMed] [Google Scholar]
  • 131.Baur A.S., Sass G., Laffert B., Willbold D., Cheng-Mayer C., Peterlin B.M. The N-terminus of Nef from HIV-1/SIV associates with a protein complex containing Lck and a serine kinase. Immunity. 1997;6:283–291. doi: 10.1016/S1074-7613(00)80331-3. [DOI] [PubMed] [Google Scholar]
  • 132.Fackler O.T., Luo W., Geyer M., Alberts A.S., Peterlin B.M. Activation of Vav by Nef induces cytoskeletal rearrangements and downstream effector functions. Mol Cell. 1999;3:729–739. doi: 10.1016/S1097-2765(01)80005-8. [DOI] [PubMed] [Google Scholar]
  • 133.Simmons A., Aluvihare V., McMichael A. Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity. 2001;14:763–777. doi: 10.1016/S1074-7613(01)00158-3. [DOI] [PubMed] [Google Scholar]
  • 134.Linnemann T., Zheng Y.H., Mandic R., Peterlin B.M. Interaction between Nef and phosphatidylinositol-3-kinase leads to activation of p21-activated kinase and increased production of HIV. Virology. 2002;294:246–255. doi: 10.1006/viro.2002.1365. [DOI] [PubMed] [Google Scholar]
  • 135.Wolf D., Witte V., Laffert B., et al. HIV-1 Nef associated PAK and PI3-kinases stimulate Aktindependent Bad phosphorylation to induce anti-apoptotic signals. Nat Med. 2001;11:1217–1224. doi: 10.1038/nm1101-1217. [DOI] [PubMed] [Google Scholar]
  • 136.Geleziunas R., Xu W., Takeda K., Ichijo H., Greene W.C. HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell. Nature. 2001;410:834–838. doi: 10.1038/35071111. [DOI] [PubMed] [Google Scholar]
  • 137.Ensoli B., Barillari G., Salahuddin S.Z., Gallo R.C., Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi’s sarcoma lesions of AIDS patients. Nature. 1990;345:84–86. doi: 10.1038/345084a0. [DOI] [PubMed] [Google Scholar]
  • 138.Albini A., Benelli R., Presta M., et al. HIV-tat protein is a heparin-binding angiogenic growth factor. Oncogene. 1996;12:289–297. [PubMed] [Google Scholar]
  • 139.Ensoli B., Buonaguro L., Barillari G., et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol. 1993;67:277–287. doi: 10.1128/jvi.67.1.277-287.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 140.Cantaluppi V., Biancone L., Boccellino M., et al. HIV type 1 Tat protein is a survival factor for Kaposi’s sarcoma and endothelial cells. AIDS Res Hum Retroviruses. 2001;17:965–976. doi: 10.1089/088922201750290087. [DOI] [PubMed] [Google Scholar]
  • 141.Deregibus M.C., Cantaluppi V., Doublier S., et al. HIV-1-Tat protein activates phosphatidylinositol 3-kinase/ AKT-dependent survival pathways in Kaposi’s sarcoma cells. J Biol Chem. 2002;277:25195–25202. doi: 10.1074/jbc.M200921200. [DOI] [PubMed] [Google Scholar]

Articles from Apoptosis, Cell Signaling, and Human Diseases are provided here courtesy of Nature Publishing Group

RESOURCES